Agenda - HMA/EMA Annual Data Forum 2025

Human medicines European public assessment report (EPAR): Rivastigmine Sandoz, rivastigmine, Date of authorisation: 10/12/2009, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Rivastigmine Hexal, rivastigmine, Date of authorisation: 11/12/2009, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Rivastigmine 1 A Pharma, rivastigmine, Date of authorisation: 11/12/2009, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Zinplava, bezlotoxumab, Date of authorisation: 18/01/2017, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Efficib, sitagliptin,metformin, Date of authorisation: 15/07/2008, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR): Aimovig, erenumab, Date of authorisation: 26/07/2018, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Akynzeo, netupitant,palonosetron, Date of authorisation: 27/05/2015, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Briviact (in Italy: Nubriveo), brivaracetam, Date of authorisation: 13/01/2016, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Tesavel, sitagliptin, Date of authorisation: 10/01/2008, Revision: 29, Status: Authorised